BioCryst Pharmaceuticals
BCRX
BCRX
292 hedge funds and large institutions have $1.77B invested in BioCryst Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 112 increasing their positions, 84 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
292
Holders Change
+20
Holders Change %
+7.35%
% of All Funds
3.92%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
52
Increased
112
Reduced
84
Closed
30
Calls
$12.7M
Puts
$6.52M
Net Calls
+$6.18M
Net Calls Change
+$1.41M
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$36.6M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$32.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$28.8M |
| 4 |
Morgan Stanley
New York
|
+$27.2M |
| 5 |
D.E. Shaw & Co
New York
|
+$25.1M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$37.6M |
| 2 |
CP
Caligan Partners
New York
|
-$22.1M |
| 3 |
Millennium Management
New York
|
-$17.1M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$14.7M |
| 5 |
Alkeon Capital Management
New York
|
-$13.4M |
